№ files_lp_4_process_3_112072
File format: docx
Character count: 7876
File size: 374 KB
This document outlines a project aimed at improving asthma management by ensuring adherence to updated guidelines for patients at risk of poor outcomes due to inappropriate use of short-acting beta 2 agonists (SABA).
Year:
2024
Region / City:
Lancashire and South Cumbria
Topic:
Asthma Management
Document Type:
Standard Operating Procedure
Organization:
NHS
Author:
Unknown
Target Audience:
Healthcare professionals, particularly those involved in asthma management
Action Period:
Ongoing
Approval Date:
November 2024
Modification Date:
None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Note:
Year
Document Type:
Job Description
Organization:
Peabody
Year:
2022
Region / City:
Bristol
Topic:
Medicines Optimisation, Pharmacy Support
Document Type:
Training Programme
Institution:
University Hospitals Bristol and Weston NHS Foundation Trust
Author:
Pharmacy Workforce Development South (PWDS)
Target Audience:
Pharmacy Support Staff
Period of Validity:
Ongoing
Approval Date:
January 2022
Date of Changes:
None
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines Optimisation, SGLT2 inhibitors
Document Type:
Protocol
Author:
NHS England
Target Audience:
Healthcare professionals, clinicians, systems involved in diabetes and heart failure treatment
Period of Validity:
Ongoing
Approval Date:
September 25, 2023
Date of Changes:
Not specified
Clinical Area:
Type 2 diabetes, heart failure, chronic kidney disease
Inclusion Criteria:
Patients aged 18 years and older prescribed empagliflozin, canagliflozin, ertugliflozin, or branded dapagliflozin for T2DM and/or HF
Exclusion Criteria:
Severe renal impairment, diabetic ketoacidosis, and other contraindications as per SPC
Background:
Dapagliflozin is now the first-line SGLT2i in England due to cost reduction following patent expiry.
Implementation Date:
Not specified
Post-switch:
No need for additional eGFR monitoring unless clinical concerns arise
Description:
Protocol outlining the process for switching eligible patients from other SGLT2 inhibitors to dapagliflozin for the management of Type 2 diabetes and heart failure in primary care.
Year:
2023
Region / city:
United Kingdom
Topic:
Medicines optimisation, SGLT2 inhibitors, diabetes, heart failure
Document type:
Protocol
Organ / institution:
NHS England
Author:
NHS
Target audience:
Clinicians, healthcare providers
Period of validity:
Ongoing
Approval date:
Not specified
Modification date:
Not specified
Document Type:
Supplementary application form
Related Form:
Case for Support
Submission System:
Je-S
Guidance Reference:
DPFS Guidance for Applicants
Purpose:
Assessment of proposals for hit to lead, lead optimisation and candidate selection funding
Confidentiality:
Information treated in strict confidence and reviewed under confidentiality agreements
Intended Users:
Applicants seeking funding
Reviewing Body:
Panel Members and External Peer Reviewers
Project Information Required:
Principal Investigator, Institution, Project Title
Scientific Scope:
Target Product Profile and Investigational New Drug parameters
Data Requirements:
Chemical structures, biological assays, physicochemical properties, DMPK, toxicology, in vivo studies
Word Limits:
20 words per TPP field; 300 words per tractability section
Organisation:
West Midlands Cancer Alliance
Programme:
MDT Optimisation Programme
Programme Manager:
Marie-Claire Wigley
Contact:
[email protected]
Region:
West Midlands
Sector:
Cancer care services
Focus:
Multi-Disciplinary Teams (MDTs)
Objectives:
Workforce development, leadership development, peer review reinstatement, treatment variation reduction
Key Activities:
MDT Coordinator Forum, Leadership Development Webinars, Peer Review Process
Target Audience:
Core clinical MDT members including Chairs, Deputy Chairs, Clinical Nurse Specialists, Allied Health Professionals, Radiologists, Oncologists, MDT Coordinators
Webinar Period:
June to October 2025
Follow-up Session:
Four months after October 2025
Next MDT Coordinator Forum Date:
3 July 2025
Quality Assurance Context:
Resumption of SSQD data collection and local peer review visits
Related Programme:
Specialised Services Quality Dashboard (SSQD)
Year:
2023
Region / city:
United Kingdom
Topic:
Medicine optimisation, diabetes, heart failure, chronic kidney disease
Document type:
Protocol
Organisation:
NHS England
Author:
Not specified
Target audience:
Healthcare professionals
Period of validity:
Ongoing
Approval date:
September 25, 2023
Modification date:
Not specified
Clinical condition:
Type 2 diabetes mellitus, heart failure, chronic kidney disease
Medication:
Dapagliflozin, Empagliflozin, Canagliflozin, Ertugliflozin
Intended use:
Generic dapagliflozin
Switch criteria:
Based on patient needs and clinical appropriateness
Inclusion criteria:
Patients aged 18 years and older currently prescribed certain SGLT2 inhibitors
Exclusion criteria:
History of adverse reactions or specific clinical conditions
Recommended dosage:
10mg once daily, with adjustments for hepatic or renal impairment
Monitoring:
HbA1c, blood tests, signs of infections or DKA
Drug interactions:
Fewer interactions compared to other SGLT2 inhibitors
Patient communication:
Information leaflets, SMS, letters
Post-switch monitoring:
Routine HbA1c checks, watch for DKA
Clinical recommendation:
Consider shared decision-making and patient discussions
References:
NICE guidelines, NHS guidance, formulary recommendations
Organisation:
Pharmacy Workforce Development South, University Hospitals Bristol and Weston NHS Foundation Trust
Address:
Marlborough Street, Bristol, BS2 8HW
Contact Telephone:
0117 342 6677
Email:
[email protected]
Website:
www.PWDS.nhs.uk
Programme Title:
Medicines Optimisation Training Programme for Pharmacy Support Staff
Unit:
Manage Patient Medication Requirements (Unit 1.1)
Document Type:
Educational Supervisor Guide
Version:
1.0
Publication Date:
January 2022
Subject Area:
Medicines optimisation, pharmacy practice, workforce development
Intended Audience:
Educational supervisors, programme support officers, pharmacy support staff trainees
Geographical Scope:
South West England
Associated Documents:
Medicines Optimisation Training Programme Handbook; assigned learning pathway; e-portfolio documentation
Assessment Methods:
Direct observation of practical skills (DOPS), competency-based assessments, accuracy logs, summative assessment interview
Issuing Body:
Pharmacy Workforce Development South
Tender number:
LPMAT00120GX
Issue date:
25/03/2025
Closing date and time:
16/04/2025 at 14h00
Tender validity period:
180 days from the closing date and time
Clarification meeting:
Date: 03 April 2025 Time: 10H00 Venue: MS teams
Tender office:
Matimba Main Security Gate Matimba Power Station Nelson Mandela Drive Lephalale0555
Date of Issue:
25/03/2025
Contract Duration:
5 years
Region:
Lephalale
Industry:
Energy
Document Type:
Invitation to Tender
Organisation:
Eskom Holdings SOC Ltd
Target Audience:
Suppliers, Contractors
Validity Period:
180 days
Note:
Clarification Meeting
03 April 2025
Eskom Representative:
Azwifaneli Fanie Thagwana
Scope of Work:
Supply, delivery, offloading and optimisation of chemicals
Tax Requirements:
PAYE
Local Content Declaration:
Required
Year:
2019
Region / City:
United Kingdom
Theme:
Healthcare, Defence
Document Type:
Announcement
Organization:
Ministry of Defence
Author:
Defence Healthcare Delivery Optimisation Programme
Target Audience:
Healthcare providers, Defence sector professionals
Period of Validity:
April 2019 - April 2020
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Country:
Australia
Sector:
Forest and Wood Products
Training Package:
FWP Forest and Wood Products Training Package Version 5.0
Unit Code:
FWPCOT3XXX
Unit Title:
Apply principles of timber and process optimisation in sawmill operations
Unit Sector Code:
COT
Document Type:
Unit of competency and assessment requirements
Prerequisite Unit:
Nil
Regulatory Status:
No occupational licensing, legislative or certification requirements at time of publication
Subject:
Timber optimisation and material flow optimisation in sawmilling operations
Key Topics:
timber value and volume recovery; workflow optimisation; optimisation drivers; equipment performance; optimisation initiatives
Industry Context:
Sawmill operations and forest product manufacturing
Technologies Referenced:
3D scanning; X-ray scanning devices; acoustic scanning devices; automated transfer systems; computer-assisted machine centres for sawing and re-sawing
Work Areas Mentioned:
log sorting; green mill sawing; dry mill processing; grading; timber treatment
Assessment Environment:
Forest product factory setting or simulated workplace conditions
Assessment Components:
Performance Evidence; Knowledge Evidence; Assessment Conditions; Foundation Skills
Related Resource:
VETNet Companion Volumes and Implementation Guides
Year:
2016
Region / City:
N/A
Topic:
Performance Optimization, Back Test Comparison
Document Type:
Technical Report
Organization / Institution:
N/A
Author:
N/A
Target Audience:
N/A
Period of Validity:
Oct to Dec 2016
Approval Date:
N/A
Date of Changes:
N/A
Note:
Year
Topic:
Asthma Management
Document Type:
Healthcare Plan
Year:
2020
Region / City:
New Zealand
Topic:
Health assessment for police recruitment
Document Type:
Medical Questionnaire
Institution:
New Zealand Police
Author:
New Zealand Police
Target Audience:
Applicants for New Zealand Police recruitment
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2023
Region / City:
New Zealand
Topic:
Health assessment for police recruitment
Document Type:
Questionnaire
Organization:
New Zealand Police
Author:
New Zealand Police
Target Audience:
Applicants for New Zealand Police recruitment
Effective Period:
Until completion of the medical review
Approval Date:
2023
Date of Changes:
N/A
Note:
Year
Year:
2023
Region / City:
New Zealand
Topic:
Health assessment for recruitment
Document type:
Medical questionnaire
Organization / Institution:
New Zealand Police
Author:
Not specified
Target audience:
Recruitment applicants
Validity period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Year:
2021
Region / city:
West Yorkshire
Theme:
Asthma Management
Document type:
Guideline
Organization:
British Thoracic Society, National Institute for Health and Care Excellence (NICE), Global Initiative for Asthma (GINA)
Author:
Not specified
Target audience:
Healthcare professionals
Effective period:
Ongoing
Approval date:
Not specified
Revision date:
Not specified
Year:
2024
Region / city:
Canberra, ACT
Theme:
Asthma, Paediatrics, Clinical Guidelines
Document Type:
Clinical Guideline
Organization / institution:
Canberra Health Services
Author:
Paediatric Improvement Collaborative (PIC)
Target Audience:
Healthcare professionals, Paediatricians, Clinical staff
Effective period:
Indefinite
Approval date:
21/11/2024
Amendment date:
21/11/2024
Superseded document:
CHS21/253 Acute Asthma - Paediatrics (infants, children and adolescents)
Acknowledgment:
Ngunnawal people as traditional custodians of the ACT
Context:
Clinical guideline for the assessment and management of paediatric asthma within the Canberra Health Services Network.
Year:
2022
Region / City:
Australia
Subject:
Pharmacology, Pharmaceutical Benefits Scheme (PBS)
Document Type:
Submission
Organization / Institution:
Sanofi-Aventis Australia Pty Ltd
Author:
Not specified
Target Audience:
Medical practitioners, healthcare professionals
Period of validity:
Not specified
Approval Date:
3 June 2022
Date of Changes:
Not specified
Contextual Description:
A regulatory submission detailing the request for listing of dupilumab in new forms for treating severe atopic dermatitis and uncontrolled severe asthma in pediatric patients under the PBS.